14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $5.34 $19.02 Monday, 6th May 2024 NBIX stock ended at $141.71. This is 0.711% more than the trading day before Friday, 3rd May 2024. During the day the stock fluctuated 2.15% from a day low at $140.55 to a day high of $143.57.
90 days $17.30 $19.02
52 weeks $16.32 $20.85

Historical Neurocrine Biosciences prices

Date Open High Low Close Volume
May 06, 2024 $140.55 $143.57 $140.55 $141.71 473 881
May 03, 2024 $140.90 $141.69 $139.39 $140.71 604 739
May 02, 2024 $143.79 $144.09 $139.64 $139.83 862 435
May 01, 2024 $140.18 $145.22 $136.01 $143.03 1 532 946
Apr 30, 2024 $138.07 $140.47 $137.34 $137.54 946 796
Apr 29, 2024 $136.05 $139.37 $136.05 $138.89 678 365
Apr 26, 2024 $137.47 $138.61 $135.17 $135.99 698 464
Apr 25, 2024 $139.37 $139.37 $136.06 $137.76 699 886
Apr 24, 2024 $140.89 $144.70 $138.01 $138.97 850 184
Apr 23, 2024 $140.62 $145.00 $139.22 $140.09 1 567 039
Apr 22, 2024 $132.48 $134.18 $131.79 $133.66 556 639
Apr 19, 2024 $132.65 $133.08 $130.13 $132.00 508 822
Apr 18, 2024 $133.23 $134.15 $131.51 $132.54 472 561
Apr 17, 2024 $133.11 $134.44 $131.36 $133.23 538 533
Apr 16, 2024 $131.78 $135.17 $131.49 $132.99 970 524
Apr 15, 2024 $134.97 $137.00 $131.52 $131.74 755 463
Apr 12, 2024 $136.22 $137.78 $134.63 $134.66 569 356
Apr 11, 2024 $138.03 $138.67 $135.28 $135.93 796 262
Apr 10, 2024 $138.45 $140.54 $137.99 $138.09 639 112
Apr 09, 2024 $140.07 $141.38 $138.00 $138.94 568 631
Apr 08, 2024 $138.03 $139.68 $137.72 $139.44 593 740
Apr 05, 2024 $137.43 $139.75 $136.03 $138.92 458 604
Apr 04, 2024 $138.17 $140.43 $136.74 $137.61 466 912
Apr 03, 2024 $137.72 $140.19 $137.36 $137.59 582 084
Apr 02, 2024 $140.61 $140.61 $136.12 $137.74 886 142
Click to get the best stock tips daily for free!

About Neurocrine Biosciences

Neurocrine Biosciences Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ON... NBIX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT